Adjuvant Abemaciclib Plus Endocrine Therapy for HR+, HER2-, High-risk Early Breast cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-year Efficacy Outcomes

被引：0

作者：

Andre, V. ^{[1
]}

Harbeck, N. ^{[2
]}

Rastogi, P. ^{[3
,4
]}

O'Shaughnessy, J. ^{[5
]}

Boyle, F. ^{[6
]}

Cortes, J.

Rugo, H. S. ^{[7
,8
]}

Goetz, M. P. ^{[9
]}

Hamilton, E. ^{[10
]}

Huang, C. -s.

Senkus, E. ^{[11
]}

Tryakin, A. ^{[12
]}

Neven, P. ^{[13
]}

Huober, J. ^{[14
]}

Wei, R. ^{[1
]}

Munoz, M. ^{[1
]}

Antonio, B. S. ^{[1
]}

Shahir, A. ^{[1
]}

Martin, M. ^{[15
]}

Johnston, S. ^{[16
]}

机构：

[1] Eli Lilly & Co, Indianapolis, IN USA

[2] LMU Univ Hosp, Breast Ctr, Comprehens Canc Ctr Munchen, Dept Gynecol & Obstet, Munich, Germany

[3] UPMC Hillman Canc Ctr, Pittsburgh, PA USA

[4] NSABP Fdn, Pittsburgh, PA USA

[5] Baylor Univ, Texas Oncol, US Oncol, Med Ctr, Dallas, TX USA

[6] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia

[7] Int Breast Canc Ctr IBCC, Quironsalud Grp, Barcelona, Spain

[8] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, Dept Med, San Francisco, CA USA

[9] Mayo Clin, Rochester, MN USA

[10] Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA

[11] Med Univ Gdansk, Gdansk, Poland

[12] NN Blokhin Russian Canc Res Ctr, Moscow, Russia

[13] Univ Hosp Leuven, Multidisciplinary Breast Ctr, Louvain, Belgium

[14] Kantonsspital St Gallen, Breast Ctr, St Gallen, Switzerland

[15] Univ Complutense, Hosp Gen Univ Gregorio Maranon, CIBERONC, GEICAM, Madrid, Spain

[16] Royal Marsden NHS Fdn Trust, London, England

来源：

BREAST | 2025年 / 80卷

关键词：

D O I：

10.1016/j.breast.2025.103903

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P009

引用

页数：2

共 50 条

[31] Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2-, node-positive, high-risk early breast cancer in Italy [J].

Davie, Alison ;

Traore, Sory ;

Giovannitti, Massimo ;

Pompilio, Giuseppe ;

Lambton, Mark ;

Cakar, Esra ;

Chatterjee, Anuja .

GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2023, 10 :62-69

[32] Primary Outcome Analysis of Invasive Disease-Free Survival for MonarchE: Abemaciclib Combined With Adjuvant Endocrine Therapy for High-Risk Early Breast Cancer [J].

O'Shaughnessy, Joyce A. ;

Johnston, Stephen ;

Harbeck, Nadia ;

Toi, Masakazu ;

Im, Young-Hyuck ;

Reinisch, Mattea ;

Shao, Zhimin ;

Lehtinen, Pirkko Liisa Kellokumpu ;

Huang, Chiun-Sheng ;

Tryakin, Alexey ;

Goetz, Matthew ;

Rugo, Hope S. ;

Senkus, Elzbieta ;

Testa, Laura ;

Andersson, Michael ;

Tamura, Kenji ;

Steger, Guenther G. ;

Del Mastro, Lucia ;

Cox, Joanne ;

Forrester, Tammy ;

Sherwood, Sarah ;

Li, Xuelin ;

Wei, Ran ;

Martin, Miguel ;

Rastogi, Priya .

CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (02) :15-16

[33] Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial [J].

Johnston, Stephen R. D. ;

Toi, Masakazu ;

O'Shaughnessy, Joyce ;

Rastogi, Priya ;

Campone, Mario ;

Neven, Patrick ;

Huang, Chiun-Sheng ;

Huober, Jens ;

Jaliffe, Georgina Garnica ;

Cicin, Irfan ;

Tolaney, Sara M. ;

Goetz, Matthew P. ;

Rugo, Hope S. ;

Senkus, Elzbieta ;

Testa, Laura ;

Del Mastro, Lucia ;

Shimizu, Chikako ;

Wei, Ran ;

Shahir, Ashwin ;

Munoz, Maria ;

San Antonio, Belen ;

Andre, Valerie ;

Harbeck, Nadia ;

Martin, Miguel .

LANCET ONCOLOGY, 2023, 24 (01) :77-90

[34] Abemaciclib Improves Disease-Free Survival in High-Risk HR+/HER2-Early Breast Cancer [J].

不详 .

ONCOLOGIST, 2021, 26 :S5-S6

[35] Efficacy, safety and toxicity management of adjuvant abemaciclib in early stage HR+/HER2-high-risk breast cancer [J].

Sammons, Sarah ;

Moore, Heather ;

Cushman, Jaycee ;

Hamilton, Erika .

EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (08) :805-814

[36] eMonarcHER: A phase 3 study of abemaciclib plus standard adjuvant endocrine therapy in patients with HR+, HER2+, node-positive, high-risk early breast cancer. [J].

Tolaney, Sara M. ;

Fallowfield, Lesley ;

Kaufman, Peter A. ;

Ciruelos, Eva M. ;

Gainford, Mary Corona ;

Lu, Yi ;

Hurt, Karla ;

Wasserstrom, Heather Ann ;

Chen, Yanyun ;

Goel, Shom .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

[37] Factors impacting treatment with abemaciclib plus endocrine therapy in high risk early-stage HR+/HER2-breast cancer patients [J].

Kudrik, Fred J. ;

Rosenfeld, Stephan B. ;

Reganti, Sowjanya ;

Reddy, Suresh V. ;

Choksi, Rushir J. ;

Scott, Jeffrey Alan ;

Rui, Anna ;

Sharma, Anubhav ;

Sura, Teena ;

Aton, Lindsay ;

Gart, Mike ;

Lamb, Ashley ;

Morere, Lisa ;

Wang, Brandon ;

Varughese, Prateesh ;

Gorantla, Vikram C. .

JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (16_SUPPL) :e12521-e12521

[38] Adjuvant Therapy of HR+, HER2 Breast Cancer Prolonging Survival without invasive Disease in high-risk early Breast Cancer [J].

Ruedesheim, Sabine M. .

ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (7-8)

[39] Letter to the Editor for 'Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study' [J].

Harbeck, N. ;

Rastogi, P. ;

Shahir, A. ;

Johnston, S. ;

O'Shaughnessy, J. .

ANNALS OF ONCOLOGY, 2022, 33 (02) :227-228

[40] Genomic and transcriptomic profiling of primary tumors from patients with HR+, HER2-, node-positive, high-risk early breast cancer in the monarchE trial [J].

Turner, Nicholas ;

Reis-Filho, Jorge ;

Goetz, Matthew ;

Desmedt, Christine ;

Chandarlapaty, Sarat ;

Sasano, Hironobu ;

Arteaga, Carlos ;

Loi, Sherene ;

Graff, Stephanie ;

Liu, Deli ;

Rodrik-Outmezguine, Vanessa ;

Sireci, Anthony ;

Rubenstein, Cynthia Sandoval ;

Won, Helen ;

Litchfield, Lacey M. ;

Munoz, Maria ;

Johnston, Stephen .

CANCER RESEARCH, 2024, 84 (09)

← 1 2 3 4 5 →